ClinicalTrials.gg
CompletedNCT05355467Updated May 2, 2022

Efficacy and Safety of Ricovir® in Maintaining Durability of Viral Response in Chronic Hepatitis B Patients Who Have Been Treated With Viread® and Have Undetectable HBV DNA in Serum

A Phase 4 interventional study of Tenofovir disoproxil fumarate and Historical Data in Chronic Hepatitis B Infection, sponsored by Mylan (Taiwan) Ltd. Completed at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2022-05-02.

Sponsored by Mylan (Taiwan) Ltd (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Aug 2019, registered Apr 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing tenofovir in Hepatitis B, Chronic — none open to participants now, 1 under way, 1 of them phase 3. Tenofovir · Hepatitis B, Chronic.

Enrollment
43rd of 50
40 · median 117
Started
2019
with 2 others
Phase 4
22 of 50
none open now
Registered
50th of 50
by date

Among the 50 studies testing tenofovir in Hepatitis B, Chronic, this one is the 43rd largest by enrollment, is one of 3 that started in 2019, is one of 22 in phase 4, and was the 50th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

None of the 50 studies testing tenofovir in Hepatitis B, Chronic is open now. The open studies under Hepatitis B, Chronic, anywhere →

About tenofovir

Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 50 studies testing tenofovir in Hepatitis B, Chronic as a file.
02

Study summary

This is a phase IV, open label, historical controlled comparative study to evaluate the efficacy and safety of Ricovir® in maintaining durability of viral response in CHB patients who have been treated with Viread® and have undetectable HBV DNA in serum by real-time polymerase chain reaction (PCR) assay.

03

Conditions studied

  • Chronic Hepatitis B Infection

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Ricovir® Group

Inclusion criteria

Inclusion Criteria:

  • Male or female aged more than 20 years old;
  • CHB patients who have been treated with Viread® for more than 1 year;
  • Serum level is undetectable (not detected or \<20 IU/mL) at screening;
  • must be obtained before the commencement of any screening procedures or study drugs

Exclusion criteria

Exclusion Criteria:

  • Patients with active HCC or other types of ;
  • Patients with impaired renal function (defined as ≦ 30 mL/min/1.73m2);
  • Patients with hepatitis A (HAV), (HCV), hepatitis D (HDV) or (HIV) coinfection;
  • Patients with alcohol dependence or addiction;
  • Patients with hepatitis;
  • Patients with primary biliary cholangitis (PBC);
  • Pregnancy, planning on getting pregnant, or breast-feeding;
  • History of allergy, , intolerance, or experiencing severe adverse reactions to tenofovir or any ingredient of the study drug;
  • Not suitable for participating in this trial at the investigator's discretion.

Historical Control Group

Eligible individuals will be obtained from the TCVGH historical database based on matching (1:1) in terms of age (±5 years) and gender. To be eligible for the study, subjects must meet all of the following criteria:

  • Male or female aged more than 20 years old;
  • CHB patients who had been treated with Viread® for more than 1 year;
  • Patients who had discontinued Viread® therapy for at least 24 weeks during the period from January 2014 to December 2021 and had undetectable (not detected or \<20 IU/mL) in serum at the time of discontinuation;
  • Patients who have the data of HBV DNA level 24 weeks after the time of discontinuation, with a time window of +4 weeks is allowed;
  • The requirement will be waived based on the approval of IRB.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Ricovir® group

    Drug: Tenofovir disoproxil fumarate

  • Other
    Historical Control Group

    Other: Historical Data

Interventions

  • Ricovir® (tenofovir disoproxil fumarate 300 mg) 1 tablet daily. The overall treatment period is 24 weeks.

  • OtherHistorical Data

    Historical Data

06

What researchers measure

Primary outcomes

  1. Assessment of the rates of virological recurrence of HBV

    To assess the rates of virological recurrence of HBV at Week 24 with Ricovir® treatment.

    Time frame: Week 24

Secondary outcomes

  1. Comparison of the HBV DNA levels between Ricovir® group and historical control group

    To compare the HBV DNA levels at Week 24 between Ricovir® group and historical control group.

    Time frame: Week 24

  2. Comparison of the rates of virological recurrence of HBV between Ricovir® group and historical control group.

    To compare the rates of virological recurrence of HBV at Week 24 between Ricovir® group and historical control group.

    Time frame: Week 24

  3. Monitoring of Safety profile for subjects in Ricovir® group

    For subjects in Ricovir® group, physical examination, vital signs, HBV DNA level, and concomitant medications will be evaluated at Week 4, 12 and 24 after treatment. Hematology and clinical biochemistry will be performed every 12 weeks. Adverse events (AEs) will be monitored continuously during the study.

    Time frame: Up to 24 weeks

07

Study locations

1 site
  • Taichung Veterans General Hospital
    Taichung, 40705, Taiwan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Jul 2021, 22 months.

Of 63 phase 4 interventional studies under Hepatitis B, Chronic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 64. This study's 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2022
First posted
May 2, 2022
StartActual
Aug 21, 2019
Primary completionActual
Jul 13, 2021
CompletionActual
Jul 13, 2021
Last update
May 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05355467
Lead sponsor
Mylan (Taiwan) Ltd
Responsible party
Sponsor
First posted
May 2, 2022
Start date
Aug 21, 2019
Primary completion
Jul 13, 2021
Completion
Jul 13, 2021
Last update
May 2, 2022

Study contacts

Sanjay Hadigal, Dr.
study director · Mylan Pharmaceuticals Private Limited

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir

Start the discussion